VectivBio Holding AG (VECT)

NASDAQ: VECT · IEX Real-Time Price · USD
7.80
-0.05 (-0.64%)
Dec 7, 2022 12:16 PM EST - Market open
-0.64%
Market Cap 492.49M
Revenue (ttm) n/a
Net Income (ttm) -87.01M
Shares Out 36.64M
EPS (ttm) -3.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,811
Open 7.79
Previous Close 7.85
Day's Range 7.75 - 7.85
52-Week Range 2.92 - 9.29
Beta n/a
Analysts Buy
Price Target 23.46 (+200.8%)
Earnings Date n/a

About VECT

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, wh... [Read more]

Industry Biotechnology
IPO Date Apr 9, 2021
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol VECT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VECT stock is "Buy." The 12-month stock price forecast is 23.46, which is an increase of 200.77% from the latest price.

Price Target
$23.46
(200.77% upside)
Analyst Consensus: Buy
Stock Forecasts

News

VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

3 weeks ago - GlobeNewsWire

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

4 weeks ago - GlobeNewsWire

VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Inve...

-Largest global Phase 3 study ever conducted in SBS-IF recruiting a total of 144 patients, stratified 50/50 for Stoma and CIC anatomical subtypes

1 month ago - GlobeNewsWire

VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

1 month ago - GlobeNewsWire

VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

1 month ago - GlobeNewsWire

VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in S...

•  Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months

1 month ago - GlobeNewsWire

VectivBio Announces Date of Extraordinary General Meeting of Shareholders

BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

1 month ago - GlobeNewsWire

VectivBio Announces Closing of $54 Million Aggregate Financing

BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

5 months ago - GlobeNewsWire

VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

Combined Gross Proceeds from Public Offering and Private Sale Total $50 Million Combined Gross Proceeds from Public Offering and Private Sale Total $50 Million

5 months ago - GlobeNewsWire

VectivBio Announces Launch of Public Offering of Ordinary Shares

BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

5 months ago - GlobeNewsWire

VectivBio Publishes Invitation to the Annual General Meeting

BASEL, Switzerland, June 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

5 months ago - GlobeNewsWire

VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graf...

– Interim proof-of-concept data anticipated from STARGAZE in H1 2023

6 months ago - GlobeNewsWire

VectivBio to Participate at the Bank of America 2022 Healthcare Conference

BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe...

6 months ago - GlobeNewsWire

VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

Arena Pharmaceuticals and Actelion veteran brings deep industry experience as VectivBio prepares for key upcoming catalysts Arena Pharmaceuticals and Actelion veteran brings deep industry experience as ...

7 months ago - GlobeNewsWire

VectivBio Reports Full Year 2021 Financial Results and Provides Business Update

Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022

8 months ago - GlobeNewsWire

VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company ...

BASEL, Switzerland, March 30, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for seve...

8 months ago - GlobeNewsWire

VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Fai...

-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease -- -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who ar...

8 months ago - GlobeNewsWire

VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48...

-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI acute graft-versus-host disease (aGVHD) --...

8 months ago - GlobeNewsWire

VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

9 months ago - GlobeNewsWire

6 Underperforming IPO Stocks To Buy On The Dip

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last y...

Other symbols: FDMTFWRGNRDSOMICPRCT
10 months ago - Benzinga

VectivBio Announces Third Quarter 2021 Business Update

-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022-

1 year ago - GlobeNewsWire

VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference

BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

1 year ago - GlobeNewsWire

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

-FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease

1 year ago - GlobeNewsWire

VectivBio Announces Closing of Comet Therapeutics Acquisition

- Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases - - Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases -

1 year ago - GlobeNewsWire

VectivBio Announces Upcoming Investor Events

Company to host an R&D Day on September 21, 2021 Company to host an R&D Day on September 21, 2021

1 year ago - GlobeNewsWire